{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:14Z","timestamp":1789609094294,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lyell\u2019s syndrome, or toxic epidermal necrolysis (TEN) is a rare but life-threatening condition. It manifests with blistering of skin and mucous due to subepidermal bullae and keratinocyte necrosis. In most cases, it is an immune response to drugs or their metabolites. The mortality in TEN is high despite optimal infection and wound control. There are no unequivocal treatment guidelines in TEN. Immunosuppressive treatment may increase the wound infection risk and mortality. The aim of the study was to evaluate a 10-year experience with immunomodulatory therapy in TEN. We perform a combination of plasmapheresis and intravenous immunoglobulins to control the disease. There were 35 patients in the group and we performed a post hoc evaluation. Twenty-eight patients received the full protocol and there were seven patients who did not complete the treatment (single therapy group). The mortality in the test group was 14.29%, and the difference reached statistical significance in comparison with the single therapy group (P &amp;lt; .05). Our protocol reduced the mortality risk five times. Our study proved that simultaneous plasmaphereses with intravenous immunoglobulins administration were safe and improved patients\u2019 outcome in TEN.<\/jats:p>","DOI":"10.1093\/jbcr\/irac046","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T12:01:50Z","timestamp":1649505710000},"page":"1394-1398","source":"Crossref","is-referenced-by-count":7,"title":["Immunomodulatory Treatment of Lyell\u2019s Syndrome: A Simultaneous Plasmapheresis and Intravenous Immunoglobulins Therapy"],"prefix":"10.1093","volume":"43","author":[{"given":"Jerzy","family":"Stru\u017cyna","sequence":"first","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"},{"name":"Department of Plastic Surgery, Reconstructive Surgery and Burn Treatment, Medical University of Lublin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-716X","authenticated-orcid":false,"given":"Agnieszka","family":"Surowiecka","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Korzeniowski","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"},{"name":"Chair and Department of Didactics and Medical Simulation , Medical University of Lublin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Piszczek","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"},{"name":"Department of Plastic Surgery, Reconstructive Surgery and Burn Treatment, Medical University of Lublin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Korulczyk","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Drozd","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldona","family":"Stachura","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Torres","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"},{"name":"Chair and Department of Didactics and Medical Simulation , Medical University of Lublin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Krajewski","sequence":"additional","affiliation":[{"name":"East Center of Burns Treatment and Reconstructive Surgery, Medical University of Lublin , \u0141\u0119czna , Poland"},{"name":"Chair and Department of Didactics and Medical Simulation , Medical University of Lublin , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"2022110208594831000_CIT0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022110208594831000_CIT0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/TME.0000000000000225","article-title":"A review of the management of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"41","author":"Woolum","year":"2019","journal-title":"Adv Emerg Nurs J"},{"key":"2022110208594831000_CIT0003","doi-asserted-by":"crossref","first-page":"e14656","DOI":"10.1111\/dth.14656","article-title":"Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: a case report","volume":"34","author":"Emadi","year":"2021","journal-title":"Dermatol Ther"},{"key":"2022110208594831000_CIT0004","doi-asserted-by":"crossref","first-page":"11.","DOI":"10.1038\/s41572-020-0145-5","article-title":"Burn injury","volume":"6","author":"Jeschke","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2022110208594831000_CIT0005","doi-asserted-by":"crossref","first-page":"6928363","DOI":"10.1155\/2017\/6928363","article-title":"Immunohistopathological findings of severe cutaneous adverse drug reactions","volume":"2017","author":"Orime","year":"2017","journal-title":"J Immunol Res"},{"key":"2022110208594831000_CIT0006","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jbcr\/irz073","article-title":"Toxic epidermal necrolysis therapy with TPE and IVIG\u201410 years of experience of the burns treatment center","volume":"40","author":"Krajewski","year":"2019","journal-title":"J Burn Care Res"},{"key":"2022110208594831000_CIT0007","first-page":"259","article-title":"Lyell\u2019s syndrome. Treatment by plasma exchange","volume":"5","author":"Gerard","year":"1984","journal-title":"Plasma Ther"},{"key":"2022110208594831000_CIT0008","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"2022110208594831000_CIT0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"2022110208594831000_CIT0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"2022110208594831000_CIT0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5603\/AIT.2013.0002","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiol Intensive Ther"},{"key":"2022110208594831000_CIT0012","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1744-9987.2009.00800.x","article-title":"Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis","volume":"14","author":"Szczeklik","year":"2010","journal-title":"Ther Apher Dial"},{"key":"2022110208594831000_CIT0013","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1590\/abd1806-4841.20187725","article-title":"Toxic epidermal necrosis induced by carbamazepine embedded in the subcutis","volume":"93","author":"Liu","year":"2018","journal-title":"An Bras Dermatol"},{"key":"2022110208594831000_CIT0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjd.17841","article-title":"British Association of Dermatologists\u2019 guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in children and young people, 2018","volume":"181","author":"McPherson","year":"2019","journal-title":"Br J Dermatol"},{"key":"2022110208594831000_CIT0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"2022110208594831000_CIT0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study","volume":"42","author":"Han","year":"2017","journal-title":"J Crit Care"},{"key":"2022110208594831000_CIT0017","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2022110208594831000_CIT0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","article-title":"A review of toxic epidermal necrolysis management in Japan","volume":"66","author":"Kinoshita","year":"2017","journal-title":"Allergol Int"},{"key":"2022110208594831000_CIT0019","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2022110208594831000_CIT0020","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2022110208594831000_CIT0021","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"2022110208594831000_CIT0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"2022110208594831000_CIT0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/15569527.2016.1218501","article-title":"Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell\u2019s syndrome)","volume":"36","author":"Monteiro","year":"2017","journal-title":"Cutan Ocul Toxicol"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irac046\/43490904\/irac046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/43\/6\/1394\/46686137\/irac046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/43\/6\/1394\/46686137\/irac046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T09:04:43Z","timestamp":1667379883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/43\/6\/1394\/6565795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,9]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irac046","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,4,9]]}}}